Helen I. Torley's most recent trade in Halozyme Therapeutics Inc. was a trade of 1,923 Common Stock done at an average price of $12.1 . Disclosure was reported to the exchange on July 8, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 08 Jul 2026 | 1,923 | 769,703 (0%) | 0% | 12.1 | 23,211 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2026 | 1,923 | 0 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 80.19 per share. | 08 Jul 2026 | 1,035 | 767,780 (0%) | 0% | 80.2 | 82,994 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 79.28 per share. | 08 Jul 2026 | 888 | 768,815 (0%) | 0% | 79.3 | 70,397 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 20,000 | 31,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 20,000 | 11,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 01 Jun 2026 | 20,000 | 787,780 (0%) | 0% | 12.1 | 241,400 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 01 Jun 2026 | 20,000 | 787,780 (0%) | 0% | 12.1 | 241,400 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 66.31 per share. | 01 Jun 2026 | 16,600 | 771,180 (0%) | 0% | 66.3 | 1,100,812 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 67.41 per share. | 01 Jun 2026 | 12,989 | 773,181 (0%) | 0% | 67.4 | 875,588 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 10,000 | 1,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 01 Jun 2026 | 10,000 | 777,780 (0%) | 0% | 12.1 | 120,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 69.69 per share. | 01 Jun 2026 | 6,100 | 767,780 (0%) | 0% | 69.7 | 425,121 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.35 per share. | 01 Jun 2026 | 5,401 | 767,780 (0%) | 0% | 68.3 | 369,137 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 66.74 per share. | 01 Jun 2026 | 3,400 | 767,780 (0%) | 0% | 66.7 | 226,933 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.74 per share. | 01 Jun 2026 | 2,000 | 773,880 (0%) | 0% | 68.7 | 137,472 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 66.39 per share. | 01 Jun 2026 | 1,610 | 786,170 (0%) | 0% | 66.4 | 106,885 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 67.68 per share. | 01 Jun 2026 | 1,500 | 775,880 (0%) | 0% | 67.7 | 101,513 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 66.37 per share. | 01 Jun 2026 | 400 | 777,380 (0%) | 0% | 66.4 | 26,547 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 20,000 | 61,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 20,000 | 81,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 11 May 2026 | 20,000 | 787,780 (0%) | 0% | 12.1 | 241,400 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 11 May 2026 | 20,000 | 787,780 (0%) | 0% | 12.1 | 241,400 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2026 | 10,000 | 51,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 11 May 2026 | 10,000 | 777,780 (0%) | 0% | 12.1 | 120,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 71.37 per share. | 11 May 2026 | 9,802 | 776,480 (0%) | 0% | 71.4 | 699,569 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.63 per share. | 11 May 2026 | 9,725 | 778,055 (0%) | 0% | 64.6 | 628,536 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 66.33 per share. | 11 May 2026 | 6,700 | 767,780 (0%) | 0% | 66.3 | 444,391 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 72.15 per share. | 11 May 2026 | 5,900 | 770,580 (0%) | 0% | 72.1 | 425,673 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 69.79 per share. | 11 May 2026 | 3,950 | 768,380 (0%) | 0% | 69.8 | 275,659 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 65.46 per share. | 11 May 2026 | 3,575 | 774,480 (0%) | 0% | 65.5 | 234,012 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.88 per share. | 11 May 2026 | 3,350 | 772,330 (0%) | 0% | 68.9 | 230,748 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 73.12 per share. | 11 May 2026 | 2,800 | 767,780 (0%) | 0% | 73.1 | 204,739 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.10 per share. | 11 May 2026 | 2,100 | 775,680 (0%) | 0% | 68.1 | 143,014 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 70.29 per share. | 11 May 2026 | 1,398 | 786,282 (0%) | 0% | 70.3 | 98,261 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 70.81 per share. | 11 May 2026 | 600 | 767,780 (0%) | 0% | 70.8 | 42,487 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 67.85 per share. | 11 May 2026 | 100 | 787,680 (0%) | 0% | 67.9 | 6,785 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2026 | 10,000 | 101,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 06 Apr 2026 | 10,000 | 777,780 (0%) | 0% | 12.1 | 120,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 63.14 per share. | 06 Apr 2026 | 5,900 | 771,880 (0%) | 0% | 63.1 | 372,520 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.02 per share. | 06 Apr 2026 | 4,100 | 767,780 (0%) | 0% | 64.0 | 262,462 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 20,000 | 131,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 20,000 | 111,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 01 Apr 2026 | 20,000 | 787,780 (0%) | 0% | 12.1 | 241,400 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 01 Apr 2026 | 20,000 | 787,780 (0%) | 0% | 12.1 | 241,400 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 65.36 per share. | 01 Apr 2026 | 19,000 | 768,780 (0%) | 0% | 65.4 | 1,241,802 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.06 per share. | 01 Apr 2026 | 15,800 | 771,980 (0%) | 0% | 64.1 | 1,012,195 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.89 per share. | 01 Apr 2026 | 4,200 | 767,780 (0%) | 0% | 64.9 | 272,525 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 65.71 per share. | 01 Apr 2026 | 1,000 | 767,780 (0%) | 0% | 65.7 | 65,714 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 92,714 | 92,714 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 53,847 | 53,847 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 50,013 | 50,013 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 24,985 | 144,400 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 19,807 | 51,171 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2026 | 20,000 | 231,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2026 | 20,000 | 211,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 03 Feb 2026 | 20,000 | 728,719 (0%) | 0% | 12.1 | 241,400 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 03 Feb 2026 | 20,000 | 728,719 (0%) | 0% | 12.1 | 241,400 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 77.54 per share. | 03 Feb 2026 | 10,100 | 708,719 (0%) | 0% | 77.5 | 783,154 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2026 | 10,000 | 201,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 03 Feb 2026 | 10,000 | 718,719 (0%) | 0% | 12.1 | 120,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 76.94 per share. | 03 Feb 2026 | 9,900 | 718,819 (0%) | 0% | 76.9 | 761,666 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 75.94 per share. | 03 Feb 2026 | 9,659 | 716,509 (0%) | 0% | 75.9 | 733,543 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 76.73 per share. | 03 Feb 2026 | 7,790 | 708,719 (0%) | 0% | 76.7 | 597,758 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 78.38 per share. | 03 Feb 2026 | 5,376 | 713,343 (0%) | 0% | 78.4 | 421,366 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 78.94 per share. | 03 Feb 2026 | 4,624 | 708,719 (0%) | 0% | 78.9 | 365,000 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.88 per share. | 03 Feb 2026 | 2,551 | 726,168 (0%) | 0% | 74.9 | 191,016 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2025 | 165,522 | 165,522 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Nov 2025 | 25,000 | 708,719 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2025 | 16,569 | 0 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 26 Nov 2025 | 16,569 | 725,288 (0%) | 0% | 8.1 | 134,375 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.51 per share. | 26 Nov 2025 | 10,406 | 714,882 (0%) | 0% | 68.5 | 712,936 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 69.44 per share. | 26 Nov 2025 | 5,402 | 709,480 (0%) | 0% | 69.4 | 375,120 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 70.36 per share. | 26 Nov 2025 | 500 | 708,980 (0%) | 0% | 70.4 | 35,181 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 71.60 per share. | 26 Nov 2025 | 261 | 708,719 (0%) | 0% | 71.6 | 18,688 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 10 Nov 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 20,000 | 16,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 20,000 | 36,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 20,000 | 56,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 10 Nov 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 10 Nov 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.71 per share. | 10 Nov 2025 | 19,900 | 733,819 (0%) | 0% | 68.7 | 1,367,409 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 70.22 per share. | 10 Nov 2025 | 12,718 | 741,001 (0%) | 0% | 70.2 | 893,033 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 69.73 per share. | 10 Nov 2025 | 11,500 | 733,719 (0%) | 0% | 69.7 | 801,907 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 71.09 per share. | 10 Nov 2025 | 6,784 | 734,217 (0%) | 0% | 71.1 | 482,268 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 67.89 per share. | 10 Nov 2025 | 4,500 | 749,219 (0%) | 0% | 67.9 | 305,514 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.80 per share. | 10 Nov 2025 | 4,000 | 745,219 (0%) | 0% | 68.8 | 275,180 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 71.67 per share. | 10 Nov 2025 | 498 | 733,719 (0%) | 0% | 71.7 | 35,690 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 69.30 per share. | 10 Nov 2025 | 100 | 733,719 (0%) | 0% | 69.3 | 6,930 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 01 Oct 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 20,000 | 76,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 20,000 | 96,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 20,000 | 116,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 01 Oct 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 01 Oct 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.47 per share. | 01 Oct 2025 | 14,235 | 739,484 (0%) | 0% | 68.5 | 974,699 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 75.11 per share. | 01 Oct 2025 | 11,705 | 742,014 (0%) | 0% | 75.1 | 879,151 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 71.28 per share. | 01 Oct 2025 | 10,200 | 736,919 (0%) | 0% | 71.3 | 727,036 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 75.69 per share. | 01 Oct 2025 | 8,295 | 733,719 (0%) | 0% | 75.7 | 627,873 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 70.51 per share. | 01 Oct 2025 | 6,600 | 747,119 (0%) | 0% | 70.5 | 465,359 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 70.58 per share. | 01 Oct 2025 | 2,707 | 734,443 (0%) | 0% | 70.6 | 191,065 | Common Stock |